Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK (GSK) Q4 Earnings and Revenues Top Estimates
08:17am, Wednesday, 01'st Feb 2023
Glaxo (GSK) delivered earnings and revenue surprises of 8.47% and 4.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
GSK 'beats the Street'; enters '23 with strong momentum
02:44am, Wednesday, 01'st Feb 2023
GSK PLC (LSE:GSK, NYSE:GSK) has reported better-than-expected fourth-quarter results, largely due to strong sales of its popular shingles vaccine, Shingrix. The pharma giant, which spun out its Haleon
GSK posts higher sales and profit of $1.85 billion, lifted by specialty medicines and vaccines businesses
02:43am, Wednesday, 01'st Feb 2023
GSK PLC on Wednesday posted rising earnings and sales for the fourth quarter, which the company said were boosted by its specialty medicines and vaccines businesses.
GSK Q4 results beat expectations, helped by Shingrix
02:20am, Wednesday, 01'st Feb 2023
GSK on Wednesday beat fourth-quarter profit and sales forecasts helped by sales of its blockbuster shingles vaccine Shingrix.
GSK, Vodafone and Entain all updating, Wednesday's agenda
09:01am, Tuesday, 31'st Jan 2023
Kicking off the new month are a trio of intriguing London blue-chips, with the US Fed decision to grab all the headlines later. In London, heavyweight pharma contender GSK PLC (LSE:GSK, NYSE:GSK),
GSK: A Defensive With A Healthy Dividend Yield
08:00pm, Monday, 30'th Jan 2023
Pharmaceuticals company GSK has seen a nice run up in price in Q4 2022. But with a rotation in favour of consumer stocks, can this continue? Its upcoming results could be an indicator. With earnings g
The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs. Pfizer, GSK
09:56am, Monday, 30'th Jan 2023
The Food and Drug Administration granted Moderna's experimental RSV vaccine an expedited review, but Moderna stock dipped Monday. The post The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs
GSK financials should look good but clinic is the focus
07:37am, Friday, 27'th Jan 2023
GSK has done well enough since the Haleon consumer products arm was spun out last year, though after a decent run-up to the end of 2022, shares have gone a bit flat since. Fourth quarter and final res
How Could GSK's RSV Vaccine Change its Valuation?
01:45am, Friday, 27'th Jan 2023
GSK plc (NYSE: GSK) is in the running with Moderna Inc. (NASDAQ: MRNA) and Pfizer (NYSE: PFE) to produce respiratory syncytial virus (RSV) vaccines, and analysts outside the company predict it could h
GSK faces new RSV vaccine competitor after Moderna data, says Barclays
03:55am, Friday, 20'th Jan 2023
GSK is facing a new competitor for its respiratory syncytial virus RSV vaccine after Moderna published data for its alternative, according to analysts at Barclays. “Moderna's efficacy data looks in
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
01:41pm, Thursday, 19'th Jan 2023
Big Pharma stalwarts are on the brink of launching the first-ever RSV vaccines, potentially enriching the pharmaceutical stocks. The post Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Crack
Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up
05:03pm, Tuesday, 17'th Jan 2023
Moderna stock jumped late Tuesday after the company said its experimental RSV vaccine proved nearly 84% effective in older adults. The post Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle
GSK growing optimistic on HIV but long term challenges remain - analyst
07:51am, Wednesday, 11'th Jan 2023
GSK PLC (LSE:GSK, NYSE:GSK) is growing at a "robust" rate and showing increasing confidence in its HIV treatments, according to Jefferies analysts, though they cut their share price target due to long
GSK plc (GSK) Presents at 41st Annual JPMorgan Healthcare Conference (Transcript)
01:40pm, Tuesday, 10'th Jan 2023
GSK plc (NYSE:GSK ) 41st Annual JPMorgan Healthcare Conference January 10, 2023 10:30 AM ET Company Participants Emma Walmsley - Chief Executive Officer Luke Miels - Chief Commercial Officer David Red
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
01:33pm, Monday, 09'th Jan 2023
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
